Combigan more cost-effective than Cosopt

Article

The fixed combination of brimonidine/timolol is more cost effective than dorzolamide/timolol, according to a study published in the September/October issue of the European Journal of Ophthalmology.

The fixed combination of brimonidine/timolol (Combigan;Allergan) is more cost effective than dorzolamide/timolol (Cosopt; Merck), according to a study published in the September/October issue of the European Journal of Ophthalmology.

A. Hommer, of the Krankenanstalt Sanatorium, Vienna, Austria, and colleagues conducted a review of the literature concerning the efficacy, tolerability and cost implications (across several European countries) of various IOP-lowering therapies administered for a three-month period.

The researchers determined equal efficacy of brimonidine 0.2% and dorzolamide 2% as either fixed combinations with or as adjunctives to timolol 0.5% therapy. At three and 12 months, however, the brominidine/timolol fixed combination proved to be the least costly option. Brimonidine as an adjunct to timolol was a more expensive alternative than the fixed combination, and dorzolamide as an adjunct to timolol represented a still more expensive option.

The team concluded that, as the efficacy was equal but the cost was lower, the brominidine/timolol fixed combination offered the greatest cost effectiveness in all countries studied of the IOP-lowering therapies reviewed.

Related Videos
Ramin Tadayoni, MD, speaks with Sheryl Stevenson
Jennifer I. Lim, MD, FARVO, FASRS, Director of Retina Service, University of Illinois at Chicago
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center
Carl D. Regillo, MD, FACS, FASRS, Chief of Retina Service, Wills Eye Hospital, Philadelphia, PA
Arshad Khanani, MD, MA FASRS, on a virtual call
Penny A Asbell, MD, FACS speaks at the 2023 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.